Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

123.40 +0.40 (+0.33%)
Streaming Delayed Price Updated: 3:00 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 402,107
Open 124.35
Bid (Size) 123.40 (2)
Ask (Size) 123.61 (4)
Prev. Close 123.00
Today's Range 122.59 - 125.16
52wk Range 117.08 - 189.07
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bear of the Day: BioNTech
BioNTech was relatively obscure until the company partnered with pharmaceutical juggernaut Pfizer (PFE) to develop one of the first mRNA COVID-19 vaccines. 
Via Talk Markets
These Analysts Revise Price Targets On BioNTech After Q4 Results
BioNTech SE (NASDAQ: BNTX) reported a decline in sales for its fourth quarter. 
Via Benzinga

Performance

YTD
-16.99%
-16.99%
1 Month
-5.70%
-5.70%
3 Month
-22.81%
-22.81%
6 Month
-5.30%
-5.30%
1 Year
-25.82%
-25.82%

More News

Read More
NVIDIA To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
BioNTech Announces New ADS Repurchase Program
From BioNTech SE
Via Globe NewsWire
Why Shares of BioNTech Slumped Monday
Via The Motley Fool
BioNTech Earnings Preview
Via Benzinga
4 Analysts Have This to Say About BioNTech
Via Benzinga
Price Over Earnings Overview: BioNTech
Via Benzinga
Elon Musk-Led Neuralink Seeks Human Trial Collaborators, Credit Suisse May Face Disciplinary Action, First Citizens Takeover Silicon Valley Bank: Today's Top Stories
Via Benzinga
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday
Via Benzinga
BioNTech Is Ripe For A Rebound In 2023
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
BioNTech Stock Crumbles After 2023 Outlook Misses By Almost $3 Billion
Via Investor's Business Daily
Why BioNTech Shares Are Trading Lower Today
Via Benzinga
Earnings Scheduled For March 27, 2023
Via Benzinga
US Stocks Poised To Start New Trading Week Higher On Hopes Of Resolving Banking Crisis: Analyst Warns 'No News Would Be Good News'
Via Benzinga
BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
From BioNTech SE
Via Globe NewsWire
Could CRISPR Therapeutics Become the Next Moderna?
Via The Motley Fool
Carnival, BioNTech And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Investor Fear Increases Amid Recent Bank Concerns
Via Benzinga
7 Blue-Chip Stocks Sitting in the Sweet Spot
Via InvestorPlace
China's First mRNA Vaccine: Drugmaker CSPC Wins China's Approval For COVID-19 Vaccine
Via Benzinga
Additional COVID-19 Booster Shots? Officials Anticipate FDA Authorization Within Few Weeks
Via Benzinga
Covid Vaccine Battle Brewing: Moderna's Stephane Bancel Vs. Bernie Sanders
Via Investor's Business Daily
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
Via Benzinga
Moderna Wants To Charge About $130 Per COVID-19 Vaccine Dose
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.